Prostate Cancer

Clinical applications of image-based radiation therapy for the study of prostate cancer have expanded significantly over the past years. The results of recent studies of magnetic resonance imaging (MRI) combined with magnetic

Clinical applications of image-based radiation therapy for the study of prostate cancer have expanded significantly over the past years. The results of recent studies of magnetic resonance imaging (MRI) combined with magnetic

The National Cancer Institute (NCI) and the Community Cancer Research Consortium (part of the Southwest Oncology Group [SWOG]) have launched a major study examining the roles of vitamin E and selenium in the prevention of prostate

Clinical applications of image-based radiation therapy for the study of prostate cancer have expanded significantly over the past years. The results of recent studies of magnetic resonance imaging (MRI) combined with magnetic

ANAHEIM, California-In hormone-refractory prostate cancer patients, bisphosphonates can relieve painful skeletal metastases, according to a study presented at the American Urological Association annual meeting (abstract 691).

ANAHEIM, California-Prostate cancer can now be added to the list of malignancies for which nonsteroidal anti-inflammatory agents (NSAIDs) may have a protective effect, according to experimental and clinical research presented at the American Urological Association annual meeting.

ANAHEIM, California-An investigational antisense oligonucleotide directed against bcl-2 appears to help overcome the resistance of hormone-refractory prostate cancer to docetaxel (Taxotere). The combination of bcl-2 antisense (G3139, Genasense) and docetaxel, therefore, may prove to be effective in this type of cancer, researchers from the University of Texas Health Science Center, San Antonio, said at the American Urological Society annual meeting (abstract 690).

EAST LANSING, Michigan-A study of 841 patients age 65 and older newly diagnosed with breast, colon, lung, or prostate cancer found three predictors of pain and fatigue: advanced stage, more comorbid conditions, and lung cancer, compared with breast cancer (the reference), according to researchers from Michigan State University.

SAN FRANCISCO-In men with localized or locally advanced prostate cancer, immediate treatment with the nonsteroidal antiandrogen bicalutamide (Casodex), alone or in addition to standard therapy, significantly reduces disease progression.

ANAHEIM, California-The timing of androgen deprivation therapy for prostate cancer may well affect disease-specific survival, according to two studies presented at the American Urological Association annual meeting.

SAN FRANCISCO-Patients with hormone-refractory prostate cancer benefited from a regimen combining paclitaxel (Taxol) and estramustine (Emcyt, Estracyt) in two phase II trials discussed at the 37th Annual Meeting of the American Society of Clinical Oncology (ASCO).

BETHESDA, Maryland-Researchers have begun accruing 32,400 men for a long-term prostate cancer study that will test whether selenium and/or vitamin E can prevent the disease. The Southwest Oncology Group (SWOG) will coordinate the Selenium and Vitamin E Cancer Trial (SELECT) at more than 400 sites in the United States, Canada, and Puerto Rico. Participants will be followed for up to 12 years.

The Food and Drug Administration (FDA) and the National Cancer Institute (NCI) inaugurated a new program in July that

Most men diagnosed with prostate cancer are more than 65 years of age. Therefore, a discussion of the issues surrounding the diagnosis, prevention, and treatment of prostate cancer in older men is, in many ways, a review of

BMS-247550 is a methyl, semi-synthetic analog of the natural product epothilone B. Provided to the National Cancer Institute (NCI) by Bristol-Myers Squibb, BMS-247550 was chosen for clinical development because it demonstrated

Most men diagnosed with prostate cancer are more than 65 years of age. Therefore, a discussion of the issues surrounding the diagnosis, prevention, and treatment of prostate cancer in older men is, in many ways, a review of

Most men diagnosed with prostate cancer are more than 65 years of age. Therefore, a discussion of the issues surrounding the diagnosis, prevention, and treatment of prostate cancer in older men is, in many ways, a review of

ANAHEIM, California-Abarelix, an injectable gonadotropin-releasing hormone (GnRH) antagonist, reduces serum prostate-specific antigen (PSA) levels and testosterone levels more than standard therapy, with less hormonal "surge," according to several studies presented at the American Urological Association (AUA) annual meeting.

ST. LOUIS-Three-dimensional (3D) conformal radiation therapy is being widely used for treatment of prostate cancer and has been successful at reducing rectal toxicities. "Conformal radiotherapy has allowed dose escalation with acceptable or even reduced rates of severe morbidity," Jeff M. Michalski, MD, reported. He added, however, that "we have to start paying attention to the low-grade morbidity. Grade 1 and grade 2 toxicity may predict development of severe late complications." Dr. Michalski is assistant professor of radiology, Mallinckrodt Institute of Radiology, Washington University, St. Louis.

DETROIT-Intrarectal topical application of amifostine (Ethyol), given as a "mini-enema," is extremely tolerable, produces no systemic toxicity, and may be an alternative to systemic administration for preventing rectal damage in patients undergoing radiotherapy for prostate cancer. Results of a phase I study were reported by Edgar Ben-Josef, MD. He is associate professor in the Department of Radiation Oncology at Wayne State University’s Karmanos Cancer Institute in Detroit.

The goal of identifying a set of pretreatment risk-stratifying factors for patients with localized prostate cancer is to be able to individualize treatment and optimize patient selection for clinical trials. Low-risk patients are most likely

The goal of identifying a set of pretreatment risk-stratifying factors for patients with localized prostate cancer is to be able to individualize treatment and optimize patient selection for clinical trials. Low-risk patients are most likely

The goal of identifying a set of pretreatment risk-stratifying factors for patients with localized prostate cancer is to be able to individualize treatment and optimize patient selection for clinical trials. Low-risk patients are most likely

SAN FRANCISCO-Atrasentan (ABT-627), an investigational endothelin-A receptor antagonist made by Abbott Laboratories, appears to delay clinical progression, PSA progression, and bone progression in hormone-refractory prostate cancer patients, according to phase II clinical trials presented at the 37th Annual Meeting of the American Society of Clinical Oncology (ASCO).

The goal of identifying a set of pretreatment risk-stratifying factors for patients with localized prostate cancer is to be able to individualize treatment and optimize patient selection for clinical trials. Low-risk patients are most likely

The Bayer Corporation announced recently that Viadur (leuprolide acetate implant), a once-yearly implant for the palliative

Phase II data presented at the 37th annual meeting of the American Society of Clinical Oncology showed that atrasentan

SAN FRANCISCO-Oral sodium clodronate appears to have delayed progression of bone metastasis from prostate cancer in a randomized clinical trial, although the results did not reach statistical significance. British investigator David Dearnaley, MD, presented the preliminary results on behalf of the Medical Research Council (MRC) Clinical Trials Unit at the 37th Annual Meeting of the American Society for Clinical Oncology (ASCO) in San Francisco.

Metastatic spinal disease is common in patients with prostate cancer. Spinal metastases may be asymptomatic (identified during staging) or cause pain and other neurologic signs and symptoms. In approximately 30% of prostate cancer patients,

Metastatic spinal disease is common in patients with prostate cancer. Spinal metastases may be asymptomatic (identified during staging) or cause pain and other neurologic signs and symptoms. In approximately 30% of prostate cancer patients,